OTCPK:BIOG.Y

Stock Analysis Report

Executive Summary

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide.

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential and pays a dividend.

Risks

  • BioGaia is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has BioGaia's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:BIOG.Y

1.5%

US Biotechs

0.9%

US Market


1 Year Return

n/a

OTCPK:BIOG.Y

-7.3%

US Biotechs

0.3%

US Market

No trading data on BIOG.Y.

No trading data on BIOG.Y.


Share holder returns

BIOG.YIndustryMarket
7 Day0%1.5%0.9%
30 Dayn/a2.2%-1.9%
90 Dayn/a3.5%1.6%
1 Yearn/a-6.5%-7.3%2.6%0.3%
3 Yearn/a8.9%5.2%41.0%31.8%
5 Yearn/a6.6%1.6%55.2%38.0%

Price Volatility Vs. Market

How volatile is BioGaia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioGaia undervalued based on future cash flows and its price relative to the stock market?

35.22x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

BioGaia's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

BioGaia's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

BioGaia is overvalued based on earnings compared to the US Biotechs industry average.

BioGaia is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

BioGaia is poor value based on expected growth next year.


Price Based on Value of Assets

BioGaia is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is BioGaia expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

14.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

BioGaia's revenue is expected to grow by 13% yearly, however this is not considered high growth (20% yearly).

BioGaia's earnings are expected to grow by 14.4% yearly, however this is not considered high growth (20% yearly).

BioGaia's revenue growth is expected to exceed the United States of America market average.

BioGaia's earnings growth is expected to exceed the United States of America market average.

BioGaia's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

BioGaia is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).


Next Steps

Past Performance

How has BioGaia performed over the past 5 years?

11.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioGaia's year on year earnings growth rate has been positive over the past 5 years.

BioGaia's 1-year earnings growth is less than its 5-year average (4.3% vs 11.7%)

BioGaia's earnings growth has not exceeded the US Biotechs industry average in the past year (4.3% vs 78.4%).


Return on Equity

BioGaia made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).


Return on Assets

BioGaia used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

BioGaia has improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is BioGaia's financial position?


Financial Position Analysis

BioGaia is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BioGaia's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

BioGaia has no debt.

BioGaia has not taken on any debt in the past 5 years.

BioGaia has no debt, it does not need to be covered by operating cash flow.

BioGaia has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

BioGaia has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is BioGaia's current dividend yield, its reliability and sustainability?

2.69%

Expected Dividend Yield


Dividend Yield and Payments Analysis

BioGaia's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.48%).

BioGaia's dividend is below the markets top 25% of dividend payers in United States of America (3.83%).

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are well covered by earnings (2.9x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be covered by earnings (1.3x coverage).


Next Steps

Management

What is the CEO of BioGaia's salary, the management and board of directors tenure and is there insider trading?

5.4yrs

Average management tenure


CEO

Isabelle Valerie Ducellier (50yo)

0.0yrs

Tenure

kr3,674,839

Compensation

Ms. Isabelle Valerie Ghislaine Ducellier serves as the Chief Executive Officer of BioGaia AB. Ms. Ducellier has been Partner and Consultant at Anian Ab since 2016. Ms. Ducellier has been Visiting Lecturer  ...


CEO Compensation Analysis

Isabelle Valerie's remuneration is lower than average for companies of similar size in United States of America.

Insufficient data for Isabelle Valerie to compare compensation growth.


Management Age and Tenure

5.4yrs

Average Tenure

53yo

Average Age

The average tenure for the BioGaia management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

4.3yrs

Average Tenure

69yo

Average Age

The tenure for the BioGaia board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Peter Rothschild (69yo)

    Founder & Chairman

    • Tenure: 1.3yrs
    • Compensation: kr8.36m
  • Bo Möllstam (67yo)

    Acting Head of Research

    • Tenure: 0.6yrs
  • Margareta Hagman (53yo)

    Executive Vice President of Accounting

    • Tenure: 9.3yrs
  • Urban Strindlöv (55yo)

    Executive VP & VP of Sales

    • Tenure: 9.6yrs
  • Staffan Strömberg (52yo)

    Vice President of Development & Regulatory Affairs

    • Tenure: 0.0yrs
  • Isabelle Valerie Ducellier (50yo)

    Chief Executive Officer

    • Tenure: 0.0yrs
    • Compensation: kr3.67m
  • Katayoun Welin-Berger (51yo)

    Vice President of Operations

    • Tenure: 0.0yrs
  • Ulrika Köhler (53yo)

    Vice President of Marketing & Product Development

    • Tenure: 0.0yrs
  • Angelika Kjelldorff

    Vice President of Human Resources

    • Tenure: 0.6yrs
  • Marika Isberg (46yo)

    VP & General Counsel

    • Tenure: 1.5yrs

Board Members

  • Peter Rothschild (69yo)

    Founder & Chairman

    • Tenure: 1.3yrs
    • Compensation: kr8.36m
  • David E. Dangoor (70yo)

    Deputy Chairman

    • Tenure: 1.3yrs
    • Compensation: kr400.00k
  • Inger Holmström (71yo)

    Director

    • Tenure: 12.6yrs
    • Compensation: kr200.00k
  • Peter Elving (71yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: kr200.00k
  • Brit Stakston (58yo)

    Director

    • Tenure: 5.6yrs
    • Compensation: kr200.00k
  • Anthon Jahreskog (39yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: kr200.00k
  • Ewa Björling (58yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: kr200.00k

Company Information

BioGaia AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioGaia AB (publ)
  • Ticker: BIOG.Y
  • Exchange: OTCPK
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr7.229b
  • Listing Market Cap: kr744.659m
  • Shares outstanding: 17.34m
  • Website: https://www.biogaia.com

Number of Employees


Location

  • BioGaia AB (publ)
  • Kungsbroplan 3
  • Stockholm
  • Stockholm County
  • 112 27
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOG BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKMay 1998
BGLDB (Deutsche Boerse AG)YesClass B SharesDEEURMay 1998
0GTNLSE (London Stock Exchange)YesClass B SharesGBSEKMay 1998
BGAI.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDMay 1998
BIOGBsBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBSEKMay 1998
BIOG.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDApr 2013

Biography

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 00:56
End of Day Share Price2019/08/07 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.